Candel Therapeutics Company Leadership
| CADL Stock | USD 8.06 0.19 2.30% |
About 90 percent of Candel Therapeutics' insiders are activelly selling. The analysis of the overall insider sentiment regarding Candel Therapeutics suggests that many insiders are panicking. Candel Therapeutics employs about 38 people. The company is managed by 13 executives with a total tenure of roughly 89 years, averaging almost 6.0 years of service per executive, having 2.92 employees per reported executive.
Insider Sentiment 10
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-03-17 | Charles Schoch | Disposed 5000 @ 8.83 | View | ||
| 2025-01-15 | Seshu Tyagarajan | Disposed 14322 @ 7.22 | View | ||
| 2025-01-08 | Francesca Barone | Disposed 13673 @ 8.22 | View | ||
| 2024-12-16 | Paul B Manning | Acquired 1250000 @ 6 | View | ||
| 2024-11-29 | William Garrett Nichols | Disposed 13935 @ 4.56 | View | ||
| 2024-10-14 | Estuardo Aguilar-Cordova | Disposed 15000 @ 6.02 | View | ||
| 2024-10-11 | Estuardo Aguilar-Cordova | Disposed 15000 @ 6.05 | View | ||
| 2024-10-03 | Estuardo Aguilar-Cordova | Disposed 1800 @ 6.85 | View | ||
| 2024-07-17 | Seshu Tyagarajan | Disposed 14851 @ 6.47 | View | ||
| 2024-07-11 | Seshu Tyagarajan | Disposed 13330 @ 5.97 | View |
Monitoring Candel Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Candel |
Candel Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5231) % which means that it has lost $0.5231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.8068) %, meaning that it created substantial loss on money invested by shareholders. Candel Therapeutics' management efficiency ratios could be used to measure how well Candel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -1.01 this year. The value of Return On Capital Employed is expected to slide to -0.51. At this time, Candel Therapeutics' Asset Turnover is quite stable compared to the past year.Common Stock Shares Outstanding is expected to rise to about 32.3 M this year, although the value of Net Loss will most likely fall to (17.8 M).
Candel Therapeutics Workforce Comparison
Candel Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 934. Candel Therapeutics holds roughly 38.0 in number of employees claiming about 4% of equities under Health Care industry.
Candel Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Candel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Candel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Candel Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 0.3913 | 9 | 23 | 951,739 | 388,560 |
| 2024-12-01 | 0.1163 | 5 | 43 | 1,319,114 | 1,735,284 |
| 2023-12-01 | 1.0 | 5 | 5 | 611,953 | 112,847 |
| 2022-06-01 | 0.5 | 2 | 4 | 140,000 | 211,530 |
| 2022-03-01 | 2.0 | 4 | 2 | 590,000 | 48,822 |
| 2021-09-01 | 0.6071 | 17 | 28 | 4,882,012 | 6,965,723 |
Candel Therapeutics Notable Stakeholders
A Candel Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Candel Therapeutics often face trade-offs trying to please all of them. Candel Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Candel Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| FOCIS MD | CEO President | Profile | |
| Charles Schoch | Principal CFO | Profile | |
| Francesca MD | Chief Officer | Profile | |
| LLM JD | Chief Officer | Profile | |
| Nathan Caffo | Chief Officer | Profile | |
| MS MD | Chief Officer | Profile | |
| FMEDSCI MD | CEO Pres | Profile | |
| MD MS | Chief Officer | Profile | |
| Jason Amello | Chief Officer | Profile | |
| Inf MD | Founder Director | Profile | |
| Carrie Cox | Special CEO | Profile | |
| Seshu Tyagarajan | Chief Officer | Profile | |
| Ileen Winick | Chief Officer | Profile |
About Candel Therapeutics Management Performance
The success or failure of an entity such as Candel Therapeutics often depends on how effective the management is. Candel Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Candel management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Candel management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.06) | (1.01) | |
| Return On Capital Employed | (0.48) | (0.51) | |
| Return On Assets | (1.06) | (1.01) | |
| Return On Equity | (3.42) | (3.25) |
Candel Therapeutics Workforce Analysis
Traditionally, organizations such as Candel Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Candel Therapeutics within its industry.Candel Therapeutics Manpower Efficiency
Return on Candel Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 4.2M | |
| Working Capital Per Employee | 1.7M | |
| Working Capital Per Executive | 5.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.